CCL2 and neoplasm: For this in vivo study, bevacizumab (20 mg/kg, twice/week) with or without mNOX-E36 (20 mg/kg, 4 times/week) was administered intraperitoneally to CCL2-expressing U87 MG tumor-bearing rats after undergoing a pretreatment MRI.